Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya (Q46884256)

From Wikidata

Jump to navigation Jump to search

scientific article published on 7 December 2005

Language	Label	Description	Also known as
English	Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya	scientific article published on 7 December 2005

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/16388879

Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/16388879

0 references

phase I clinical trial

0 references

Plasmodium falciparum

0 references

0 references

1 reference

based on heuristic

inferred from title

Plasmodium falciparum malaria

1 reference

based on heuristic

inferred from title

malaria vaccine

1 reference

based on heuristic

inferred from title

object named as

Kent E Kester

16

0 references

20

object named as

Janet Wittes

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

Christian F Ockenhouse

17

object named as

Christian F Ockenhouse

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/16388879

13

object named as

Evelina Angov

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/16388879

D. Gray Heppner

21

object named as

D Gray Heppner

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/16388879

Denise M. McKinney

5

object named as

Denise McKinney

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/16388879

4

object named as

Joram Siangla

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/16388879

Kathryn M Tucker

9

object named as

Kathryn Tucker

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/16388879

19

object named as

Carter L Diggs

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/16388879

14

object named as

Amanda Leach

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/16388879

Lorraine A Soisson

10

object named as

Lorraine Soisson

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/16388879

Jessica B Milman

8

object named as

Jessica Milman

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/16388879

MSP-1 Malaria Vaccine Working Group

22

object named as

MSP-1 Malaria Vaccine Working Group

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/16388879

1

object named as

José A Stoute

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/16388879

author name string

Joash Gombe

2

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/16388879

Mark R Withers

3

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/16388879

Melanie Onyango

6

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/16388879

James F Cummings

7

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/16388879

V Ann Stewart

11

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/16388879

Jeffrey A Lyon

12

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/16388879

Joe Cohen

15

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/16388879

Carolyn A Holland

18

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/16388879

language of work or name

0 references

publication date

7 December 2005

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/16388879

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/16388879

25

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/16388879

1

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/16388879

176-184

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/16388879

Roll Back Malaria: a failing global health campaign

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.037

7 January 2021

The economic and social burden of malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.037

7 January 2021

The major merozoite surface protein as a malaria vaccine target

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.037

7 January 2021

Protective antigens of rodent and human bloodstage malaria.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.037

7 January 2021

Secondary processing of the Plasmodium falciparum merozoite surface protein-1 (MSP1) by a calcium-dependent membrane-bound serine protease: shedding of MSP133 as a noncovalently associated complex with other fragments of the MSP1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.037

7 January 2021

Fine specificity of serum antibodies to Plasmodium falciparum merozoite surface protein, PfMSP-1(19), predicts protection from malaria infection and high-density parasitemia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.037

7 January 2021

Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.037

7 January 2021

Human antibodies to the 19kDa C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 inhibit parasite growth in vitro

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.037

7 January 2021

A recombinant vaccine expressed in the milk of transgenic mice protects Aotus monkeys from a lethal challenge with Plasmodium falciparum

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.037

7 January 2021

Efficacy of two alternate vaccines based on Plasmodium falciparum merozoite surface protein 1 in an Aotus challenge trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.037

7 January 2021

The clinical-grade 42-kilodalton fragment of merozoite surface protein 1 of Plasmodium falciparum strain FVO expressed in Escherichia coli protects Aotus nancymai against challenge with homologous erythrocytic-stage parasites

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.037

7 January 2021

Development and pre-clinical analysis of a Plasmodium falciparum Merozoite Surface Protein-1(42) malaria vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.037

7 January 2021

Pre-clinical evaluation of the malaria vaccine candidate P. falciparum MSP1(42) formulated with novel adjuvants or with alum

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.037

7 January 2021

Phase I safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.037

7 January 2021

Characterization of malaria transmission by Anopheles (Diptera: Culicidae) in western Kenya in preparation for malaria vaccine trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.037

7 January 2021

Sequence heterogeneity of the C-terminal, Cys-rich region of the merozoite surface protein-1 (MSP-1) in field samples of Plasmodium falciparum

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.037

7 January 2021

Malaria and anemia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.037

7 January 2021

Loss of red blood cell-complement regulatory proteins and increased levels of circulating immune complexes are associated with severe malarial anemia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.037

7 January 2021

New World monkey efficacy trials for malaria vaccine development: critical path or detour?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.037

7 January 2021

Anemia in parasite- and recombinant protein-immunized aotus monkeys infected with Plasmodium falciparum.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.037

7 January 2021

The ears of the hippopotamus: manifestations, determinants, and estimates of the malaria burden

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.037

7 January 2021

based on heuristic

inferred from DOI database lookup

Age-dependent acquired protection against Plasmodium falciparum in people having two years exposure to hyperendemic malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.037

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical disease, immunity and protection against Plasmodium falciparum malaria in populations living in endemic areas

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.037

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2005.11.037

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/16388879

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/16388879

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46884256&oldid=2136196423"